近年来，革兰阴性细菌对抗菌药物的耐药性已达到临界水平，耐碳青霉烯类肺炎克雷伯杆菌（CRKP）在 多国儿科病房的检出率逐年增加。CRKP脓毒症起病隐匿，缺乏特异临床表现，但进展迅速、致病性强、易出现多器官 衰竭等，危及患儿生命。碳青霉烯类抗菌药物仍是CRKP感染的主要治疗手段。目前也有关于新型抗生素的研究。文 章对CRKP脓毒症的临床研究进展进行综述。

In recent years, the resistance of gram-negative bacteria to antibiotics has reached a critical level, and the detection rate of carbapenem-resistant Klebsiella pneumoniae (CRKP) in pediatric wards in many countries has been increasing year by year. CRKP sepsis has an insidious onset and lacks specific clinical manifestations. However, CRKP sepsis is highly pathogenic, progresses rapidly, and is prone to multiple organ failure, which can endanger the lives of children. Carbapenem antibiotics are still the main treatment for CRKP infection, and new antibiotics are also being studied. This article reviews the clinical research progress of CRKP sepsis.